Delcath Systems amended its bylaws to establish exclusive forums for litigation, designating the Delaware Court of Chancery for internal corporate claims and federal district courts for Securities Act claims. This is a standard governance update with no financial impact.

Delcath Systems reported second quarter 2026 financial results with total revenue of $29.1 million, up from $24.2 million in the prior year period. HEPZATO KIT revenue reached $27.1 million and CHEMOSAT revenue was $2.0 million. The company achieved a gross margin of 90% and reported net income of $2.7 million. Non-GAAP adjusted EBITDA decreased to $7.6 million from $9.8 million in the prior year quarter. Delcath increased its full-year 2026 revenue guidance to a range of $104 million to $108 million, reflecting at least 28% growth in HEPZATO KIT volume. The company ended the quarter with $95.9 million in cash and investments and no debt. Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.